Computationally repurposing drugs for breast cancer subtypes using a network-based approach

BMC Bioinformatics

Table 2 Top 20 drugs corresponding to subtype 1

Rank	Drug	Dosage (μm)	Treatment time (h)	Score	Drug type	References
1	Ruxolitinib	10	24	− 0.589	Approved	[51, 52]
2	Ribavirin	10	24	− 0.556	Approved	[65]
3	Deferiprone	0.04	24	− 0.534	Approved	[66, 67]
4	Tranilast	0.04	24	− 0.523	Investigational	[68]
5	Tadalafil	10	24	− 0.521	Approved
6	Rimexolone	0.04	24	− 0.515	Approved
7	Bardoxolone methyl	0.04	24	− 0.511	Investigational	[69, 70]
8	Sirolimus	0.04	24	− 0.507	Approved	[71, 72]
9	Crizotinib	0.04	24	− 0.503	Approved	[73, 74]
10	PF-04217903	0.04	24	− 0.499	Investigational
11	Dofequidar	10	24	− 0.498	Experimental	[75, 76]
12	GSK-2636771	10	24	− 0.495	Investigational
13	Edetic acid	10	24	− 0.494	Approved
14	MK-1775	10	24	− 0.490	Investigational	[77]
15	MF-101	10	24	− 0.478	Investigational
16	Ranolazine	0.04	24	− 0.476	Approved	[78]
17	Semaxanib	0.04	24	− 0.475	Experimental	[79]
18	Iniparib	10	24	− 0.474	Investigational	[80]
19	AKT-inhibitor 1/2	10	24	− 0.473	Experimental
20	Rupatadine	0.04	24	− 0.473	Approved

ISSN: 1471-2105